On the other hand, low expression of TTF2, ABCC2, FLOT2, and NLRP2 was correlated with poor prognosis in HER2-positive breast cancer patients, whereas their low expression was correlated with better prognosis in the overall METABRIC cohort. This evidence concerns the gene ERBB2 and breast carcinoma.